EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer

European Journal of Surgical Oncology

Volumn 28, Issue 4, 2002, Pages 383-387

  Tsutsui, S ^a   Ohno, S ^b   Murakami, S ^b   Kataoka, A ^b   Kinoshita, J ^b   Hachitanda, Y ^b  

^a NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Breast cancer; c erbB2; EGFR; p53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE C ERB; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 0036620235     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2002.1259     Document Type: Article

References (24)

1. Osborne CK. Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol 1985; 12: 317-26.
2. Nicholson RI, McClelland RA, Finlay P et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993; 29A: 1018-23.
3. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-6.
4. Kandioler-Eckersberger D, Ludwig C, Rudas M et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50-6.
5. Walker RA, Dearing SJ, Lane DP et al. Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol 1991; 165: 203-11.
6. Iglehart JD, Kerns B, Huper G et al. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat 1995; 34: 253-63.
7. Lacroix H, Iglehart JD, Skinner MA et al. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 1989; 4: 145-51.
8. Davidoff AM, Kerns BM, Iglehart JD et al. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991; 51: 2605-10.
9. Iglehart JD, Kraus MH, Langton BC et al. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 1990; 50: 6701-7.
10. Mori T, Morimoto T, Komaki K et al. Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer. Cancer 1991; 68: 532-7.
11. Gebhardt F, Zanker KS, Brandt B. Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micrometastases from breast cancer patients. Biochem Biophys Res Commun 1998; 247: 319-23.
12. Tsutsui S, Ohno S, Murakami S et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002; 71: 67-75.
13. Tsutsui S, Ohno S, Murakami S et al. Prognostic value of p53 protein expression in breast cancer; an immunohistochemical analysis of frozen sections in 514 Japanese women. Breast Cancer 2001; 8: 194-201.
14. Osaki A, Nomura Y. Relative effects of immunohistochemical expression of c-erbB2, p53, and bcl-2 oncoproteins on the survival of advanced breast cancer patients after endocrine therapy. Int J Oncol 1996; 9: 131-6.
15. Rosen PP, Lesser ML, Arroy CD et al. p53 in node-negative breast carcinoma: an immunohistochemnical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995; 13: 821-30.
16. Rosen PP, Menendez-Botet CJ, Urban JA et al. Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer. Cancer 1977; 39: 2194-200.
17. Rasmussen BB. Immunohistochemical detection of estrogen receptors in paraffin sections from primary and metastatic breast cancer. Pathol Res Pract 1989; 185: 856-9.
18. Kuukasjarvi T, Kononen J, Helin H et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996; 14: 2584-9.
19. Isola J, Visakorpi T, Holli K et al. Association of overexpression of tumour suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992; 84: 1109-14.
20. Klijn JGM, Berns PMJJ, Schmitz PIM et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992; 13: 156-70.
21. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791-808.
22. Birner P, Oberhuber G, Stani J et al. Evaluation of the United States Food and Drug Administration - approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001; 7: 1669-75.
23. Tsutsui S, Kuwano H, Mori M et al. A flow cytometric analysis of DNA content in primary and metastatic lesions of esophageal squamous cell carcinoma. Cancer 1992; 70: 2586-91.
24. Thor A. Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? J Natl Cancer Inst 2001; 93: 1120-1.